Novo Nordisk Takes an Early Lead in the Weight Loss Pill Race
Novo Nordisk got greenlit by the Food and Drug Administration for its daily semaglutide pill in December 2025. This approval happened months before Eli Lilly rolled out its rival pill, named Foundayo. Because of this head start, the semaglutide pill gained a massive advantage in the first few months of sales. A tracking firm called IQVIA counted these prescription numbers, and industry experts now say this lead looks permanent.
Weekly prescription data shows the gap between the two drugs very clearly. Foundayo prescriptions have flatlined at around twenty thousand orders per week for about a month. Notably, this volume matches what the semaglutide pill achieved in its very first weeks on the market. During the week ending June 26, 2026, Foundayo orders even dropped by four percent to 19,830.
Insurance coverage differences explain a huge part of this market gap. The makers of the semaglutide pill got all three major pharmacy benefit managers to cover it immediately. On the other hand, CVS did not cover Foundayo until June 1, 2026. Therefore, people who wanted the Eli Lilly pill had to pay much more out of pocket at the start.
Different results from medical tests also affect which pill doctors choose to prescribe. Published data shows that the oral semaglutide pill helped patients lose an average of 16.6 percent of their weight over 64 weeks. Meanwhile, Foundayo patients lost 12.4 percent of their weight over 72 weeks in trials. Even so, Foundayo is easier to take because patients do not have to fast before using it.
Prices complicate the battle between these two drug companies even more. Novo Nordisk set the starting price for its pill at 149 dollars each month. Eli Lilly signaled that Foundayo could cost up to 399 dollars a month for stronger doses. In view of this, both companies set up special pricing deals with federal officials to lower domestic costs.
Some financial experts warn people not to look too deeply into these early numbers. One firm noted that early sales for Foundayo are lower than what Wall Street expected. However, experts still believe the drug will hit its total 2026 sales goal of 1.2 billion dollars. Furthermore, some analysts predict Foundayo will win the long race by 2030 because it is more convenient.
Federal regulators continue to watch both weight loss products very closely. The Food and Drug Administration monitors patient health data to check for heart and stomach issues. Under national rules, patients must have an official obesity diagnosis to get either medication. Consequently, doctors must check specific health rules before writing a prescription for these therapies.
The long term impact of this race goes way beyond the first few months of sales data. Experts expect these convenient pills to make up a huge part of the global weight loss market by 2030. Therefore, winning customers early will shape the habits of doctors for a long time. As a result, both companies are spending heavily to build new factories and advertise their products.
